Sofia R. Gameiro

发表

Abstract 1676: Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.

S. Ferrone, K. Tsang, C. T. Garnett, 2013 .

Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation

Karin M. Knudson, J. Hodge, Anthony S. Malamas, 2016, Oncotarget.

Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.

J. Hodge, S. Gameiro, H. Sharp, 2012, Cancer biotherapy & radiopharmaceuticals.

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells

S. Ferrone, K. Tsang, J. Hodge, 2016, Oncotarget.

Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise

J. Hodge, S. Gameiro, Momodou L. Jammeh, 2013, Expert review of vaccines.

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Andressa Ardiani, J. Hodge, B. Farsaci, 2012, Seminars in oncology.

Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.

J. Hodge, S. Gameiro, J. A. Caballero, 2012, Cancer biotherapy & radiopharmaceuticals.

Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

J. Schlom, Andressa Ardiani, J. Hodge, 2014, Cancer research.

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

F. Marincola, P. Vandenabeele, S. Loi, 2020, Journal for ImmunoTherapy of Cancer.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

D. Cescon, B. Vincent, S. Adams, 2019, npj Breast Cancer.

Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy

L. Rohlin, S. Benz, J. Z. Sanborn, 2019, Cancer Immunology Research.

Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

S. Ferrone, K. Tsang, Max M. Wattenberg, 2014 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway

Andressa Ardiani, R. Donahue, J. Hodge, 2014, Oncotarget.

Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity

J. Schlom, Xinping Yang, James B. Mitchell, 2022, JCI insight.

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

S. Steinberg, J. Schlom, S. Lipkowitz, 2021, Frontiers in Oncology.

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

J. Schlom, J. Gulley, C. Jochems, 2020, Journal for ImmunoTherapy of Cancer.

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

J. Schlom, Karin M. Knudson, Xiaoling Luo, 2018, Oncoimmunology.

Rationale for IL-15 superagonists in cancer immunotherapy

J. Schlom, Karin M. Knudson, J. Hodge, 2020, Expert opinion on biological therapy.

Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy

J. Schlom, W. Figg, S. Rabizadeh, 2019, Clinical Cancer Research.

Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine

J. Schlom, Christine M Minnar, Grace Lui, 2024, Frontiers in oncology.

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

M. Cam, J. Schlom, Paul L. Chariou, 2021, Nature Communications.

Defining Molecular Signature of Pro-Immunogenic Radiotherapy Targets in Human Prostate Cancer Cells

C. N. Coleman, S. T. Palayoor, A. Makinde, 2014, Radiation research.

Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies

J. Schlom, P. Soon-Shiong, S. Gameiro, 2023, Cells.

The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex

C. Szeto, J. Schlom, S. Rabizadeh, 2018, Oncoimmunology.

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

Soldano Ferrone, Sofia R. Gameiro, Kwong Y. Tsang, 2013, Oncotarget.

Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9

Paul L. Chariou, Christine M Minnar, Jeffrey Schlom, 2024, PloS one.

Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses

J. Higgins, J. Hodge, S. Gameiro, 2011, Cancer Immunology, Immunotherapy.

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types

J. Schlom, Karin M. Knudson, C. Allen, 2018, Oncoimmunology.

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL

M. Brechbiel, J. Schlom, P. Kim, 2015, Journal of Immunotherapy for Cancer.

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12

J. Schlom, Paul L. Chariou, Michelle R. Padget, 2023, Cancer Immunology, Immunotherapy.

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

J. Schlom, Karin M. Knudson, S. Gameiro, 2019, Journal of Immunotherapy for Cancer.

Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities.

C. Garnett-Benson, J. Hodge, S. Gameiro, 2015, Seminars in radiation oncology.

Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status

J. Schlom, J. Gulley, S. Gameiro, 2022, Experimental biology and medicine.

Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa

J. Schlom, Karin M. Knudson, Y. Ozawa, 2021, Oncoimmunology.

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication

J. Schlom, Paul L. Chariou, S. Langermann, 2022, The Journal of clinical investigation.

Combination Therapy with Local Radiofrequency Ablation and Systemic Vaccine Enhances Antitumor Immunity and Mediates Local and Distal Tumor Regression

David L. Woods, B. Wood, C. Guha, 2013, PloS one.

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Kathleen E. Fenerty, S. Rabizadeh, P. Soon-Shiong, 2018, Journal of Immunotherapy for Cancer.

Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing.

M. Bernstein, S. Hahn, C. Guha, 2016, International journal of radiation oncology, biology, physics.

Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin

Andressa Ardiani, Jacob Richards, J. Hodge, 2016, Oncotarget.

D-104 Harnessing the potential of HDAC inhibitors for immunotherapy combinations

J. Schlom, J. Hodge, S. Gameiro, 2019, JAIDS Journal of Acquired Immune Deficiency Syndromes.

If we build it they will come: targeting the immune response to breast cancer

D. Cescon, S. Adams, H. McArthur, 2019, npj Breast Cancer.

Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions.

M. Bernstein, S. Kalnicki, C. Guha, 2014, Cancer biotherapy & radiopharmaceuticals.

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist

J. Schlom, Karin M. Knudson, Y. Ozawa, 2020, Journal for ImmunoTherapy of Cancer.

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets

A. Dicker, J. Hodge, S. Gameiro, 2014, British Journal of Cancer.

Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer

J. Schlom, R. Madan, J. Gulley, 2010, Clinical and translational science.

Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

S. Ferrone, K. Tsang, Max M. Wattenberg, 2014 .

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies

J. Schlom, J. Friedman, Lillian Sun, 2018, Journal of Immunotherapy for Cancer.